Skip to main content
. Author manuscript; available in PMC: 2017 Aug 1.
Published in final edited form as: Cancer Immunol Res. 2016 Jun 16;4(8):669–678. doi: 10.1158/2326-6066.CIR-15-0215

Figure 4.

Figure 4

Reactivity of clones or TCRs corresponding to predominant clonotypes in TIL 3713. Responses of allogeneic whole PBMC (A-C) or CD8-enriched T cells (D) transduced with TCRs reactive with the mutated SRPX (A), AFMID (B) HELZ2 (C) or CENPL epitopes were evaluated by measuring the release of IFNγ in response to T2 cells (A) or autologous EBV B cells (B-D) pulsed with the appropriate peptides. Transduced T cells were also evaluated for their ability to release IFNγ in response to either, the autologous TC line or an allogeneic melanoma TC line. In addition, T-cell clones isolated from TIL that were reactive with the mutated SRPX epitope (E) or the mutated SEC22C epitope (F) evaluated for their ability to up-regulate 4-1BB in response to autologous normal B cells (E) or EBV B cell (F) targets pulsed with the appropriate peptides or the autologous TC line (graphs represent 2 independent experimental repeats).